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Background: Highly active antiretroviral therapy (HAART) has transformed HIV-1 infection from a deadly disease to
a manageable chronic illness, albeit does not provide a cure. The recently developed genome editing system called
CRISPR/Cas9 offers a new tool to inactivate the integrated latent HIV-1 DNA and may serve as a new avenue toward
cure.
Findings: We tested 10 sites in HIV-1 DNA that can be targeted by CRISPR/Cas9. The engineered CRISPR/Cas9
system was introduced into the JLat10.6 cells that are latently infected by HIV-1. The sequencing results showed
that each target site in HIV-1 DNA was efficiently mutated by CRISPR/Cas9 with the target site in the second exon
of Rev (called T10) exhibiting the highest degree of mutation. As a result, HIV-1 gene expression and virus
production were significantly diminished with T10 causing a 20-fold reduction.
Conclusions: The CRISPR/Cas9 complex efficiently mutates and deactivates HIV-1 proviral DNA in latently infected
Jurkat cells. Our results also revealed a highly efficient Cas9 target site within the second exon of Rev that represents a
promising target to be further explored in the CRISPR/Cas9-based cure strategy.
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Current antiretroviral therapy (ART) enables control of
HIV infection at both the individual level and on a global
scale. As a result, steady declines have been seen in both
numbers of new HIV infections as well as in HIV mortal-
ity rates [1,2]. Unfortunately, a cure of HIV infection has
not yet been attained. One block to this ultimate goal is
the persistence of HIV reservoirs that cannot be cleared
by current ART [3]. The establishment of viral reservoirs
requires the integration of HIV DNA into cellular genome
[4]. Theoretically, deleting or deactivating proviral DNA
should eliminate the source of HIV persistence, and may
thus provide a valuable tool toward cure.
Two approaches have been explored in this context. One
is based on the zinc-finger nucleases (ZFNs) that were engi-
neered to recognize and cleave specific HIV DNA sequences
[5]. The second approach is called TALENS (transcription* Correspondence: zhuwjun@gmail.com; chen.liang@mcgill.ca
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unless otherwise stated.activator-like effector nucleases) that program transcription
factors to recognize specific DNA sequences [6]. Both ap-
proaches exploit the principle of protein-DNA recognition
that often involves a certain degree of ambiguity. A recent
development in genome editing is the CRISPR (Type II mi-
crobial clustered regularly interspaced short palindromic re-
peat)/Cas9 system that utilizes a guide RNA strand to
recognize and mutate target DNA; this therefore now offers
a new strategy to inactivate HIV DNA [7-10].
This CRISPR/Cas9 system arms a DNA endonuclease
called Cas9 with an RNA component that utilizes a 20-
nucleotide guide sequence (gRNA) to recognize a specific
DNA site [7,8]. Cleavage of DNA by Cas9 generates
double-stranded DNA breaks that, upon non-homologous
end joining (NHEJ) repair, cause insertions or deletions at
the DNA target sites. This approach has been demon-
strated highly specific and efficient in targeting multiple
cellular genes and has been further developed for
genome-wide screens to study gene function [11-14]. In
this study, we have tested the efficiency of the CRISPR/
Cas9 system in inactivating the integrated HIV-1 DNA in
a HIV-GFP Jurkat cell line called JLat10.6 that was devel-
oped to study HIV latency [15].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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viral DNA that is transcription silent in the absence of ex-
ternal stimulation. Treatment with cytokines such as TNF-
α activates viral gene expression, which can be measured by
monitoring the expression of GFP that has been inserted
into HIV-1 DNA as a reporter gene. In order to target
HIV-1 DNA, we surveyed the HIV-1 genome and identified
more than 80 PAM (protospacer adjacent motif) sites that
potentially allow the CRISPR/Cas9 complex to recognize
HIV-1 DNA. After considering the conservation of these
target DNA sequences across different HIV-1 strains as
well as excluding off-target possibilities by blasting the hu-
man genome, 10 gRNAs (named T1 to T10) were selected
and inserted into the gRNA-cloning vector [8]. Of these 10
target sites, 3 are located within the LTR, 5 in the pol gene,
and 2 in the second exon of tat/rev (Figure 1). We then
nucleotransfected these gRNA constructs, together with
the hCas9 plasmid DNA (expressing the humanized Cas9
enzyme) [8], into JLat10.6 cells. SURVEYOR assay was first
performed to measure the frequency of NHEJ as a result of
the targeted Cas9 cleavage of HIV-1 DNA. NHEJ was dem-
onstrated for all 10 gRNAs. The frequency ranged from
10% to 30% (Figure 2A). The targeted viral DNA regionsFigure 1 Illustration of the ten HIV-1 guide RNAs tested in this study.
Schematic depiction of binding of the T1 gRNA guide sequence (20 nucleo
The PAM (protospacer adjacent motif) is highlighted in green letters. The r
target sites in the genome HIV-1 strain HXB2 (T1 to T10). Conservation of e
each gRNA was calculated using the program at http://www.genome-engiwere also amplified by PCR and further examined by se-
quencing. Both insertions and deletions of various lengths
of nucleotides were observed, with the gRNA T10 causing
the most types of deletions and insertions (Figure 2B).
These data illustrate the effectiveness of the 10 gRNAs in
targeting Cas9 to cleave and mutate HIV-1 DNA at distinct
regions.
In order to measure the effects of gRNA/Cas9-induced
DNA mutations on the function of integrated HIV-1
DNA, we first transfected the JLat10.6 cells with gRNA/
Cas9 DNA followed by TNF-α (10 ng/ml) treatment to in-
duce viral gene expression which is monitored by scoring
GFP-positive cells by flow cytometry. The results showed
that the gRNA targeting GFP DNA (named T GFP) re-
duced GFP expression by 5-fold (Figure 3A). No effect
was observed for a gRNA that targets the renilla luciferase
(T RL) DNA. The gRNAs targeting HIV-1 DNA dimin-
ished the number of GFP-positive cells to different de-
grees, ranging from 3-fold (gRNA T3) to 20-fold (gRNA
T10) (Figure 3A). These gRNAs alone, without the help of
Cas9, exerted no effect on GFP expression (Figure 3B).
When levels of HIV-1 in culture supernatants were mea-
sured by p24 ELISA, gRNA T3 led to 3-fold diminution as(A) Locations of the 10 guide RNAs (T1 to T10) in HIV-1 genome. (B)
tides, underlined) to the HIV-1 DNA in the context of Cas9 (in yellow).
ed arrow indicates the cleavage site by Cas9. (C) Sequences of the 10
ach target sequence in HIV database is presented. The CRISPR score of
neering.org.
Figure 2 Analysis of mutations in HIV-1 DNA caused by CRISPR/Cas9 treatment. (A) Results of the SURVEYOR assays to measure the NHEJ
events resulting from HIV-1 guide RNA treatment. Data of two or three independent transfection experiments are shown. The percentage of the
mutated DNA (indicated by arrows) is presented at the bottom of each lane. (B) Mutations at each gRNA target site. The mutated sequences
(deletions, insertions and substitutions) are shown in red letters. The PAMs are highlighted in green letters. The wild type HIV-1 DNA is underlined
and shown at the top of each aligned sequence panel.
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T8 and T10 (Figure 3C). The gRNAs alone, in the absence
of Cas9, did not affect HIV-1 production (Figure 3D), which
further confirms that the gRNA molecules act on HIV-1
DNA through arming the Cas9 enzyme. Together, these
data demonstrate the high efficacy of the CRISPR/Cas9 sys-
tem in targeting and inactivating HIV-1 proviral DNA.
In JLat10.6 cells, without any external stimulation, HIV-
1 DNA is transcription silent as a result of the inaccessibil-
ity of cellular transcriptional machinery to HIV-1 LTR
promoter [15,16]. We suspect that this inaccessibility,
likely a result of modified chromatin structure, may hinder
the ability of the CRISPR/Cas9 complex to target HIV-1
DNA. Were this the case, then pretreatment with HDAC
inhibitors such as SAHA may deem necessary to activate
HIV-1 gene expression in order to enhance the effective-
ness of CRISPR/Cas9 system. We therefore treated the
JLat10.6 cells with TNF-α for 16 hours prior to nucleo-
transfection with the gRNA and hCas9 plasmid DNA. Incontrary to our expectation, activation of HIV-1 transcrip-
tion by TNF-α did not render HIV-1 DNA more susceptible
to inhibition by the CRISPR/Cas9 machinery (Figure 3E
and F). This observation suggests that the CRISPR/Cas9 sys-
tem has the ability to access transcription silent HIV-1 DNA
without the need to activate viral gene expression by TNF-α
or related agents such as SAHA. This property of the
CRISPR/Cas9 system supports its possible utility in eradica-
tion of integrated HIV-1 DNA from latently infected im-
mune cells such as CD4+ T cells and macrophages, in
which HIV-1 transcription is also inert. Given that these
HIV-1 latently-infected cells are often non-cycling, further
studies are warranted to assess whether cell cycling may
affect the efficacy of CRISPR/Cas9.
We next tested whether combinations of different
gRNAs further increased the potency of inhibition. This
combination strategy is also expected to diminish the
chances of HIV-1 to escape from gRNA targeting. Indeed,
certain combinations, such as T1/T6/T9, T2/T4/T10 and
Figure 3 (See legend on next page.)
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Figure 3 Suppression of HIV-1 gene expression and virus production by gRNA/Cas9. (A, B) Effects of gRNA/Cas9 on GFP expression. JLat10.6 cells
were transfected with gRNA and hCas9 plasmid DNA using Neon (Life Technologies). TNF-α (10 ng/ml) was added 16 hours after to stimulate HIV-1 gene
expression from HIV-1 LTR promoter, which was monitored by flow cytometry. A gRNA targeting the GFP DNA (called T GFP (GTGAACCGCATCGAGCTGAA))
was included as a positive control. The gRNA targeting renilla luciferase DNA (called T RL (GTAGCGCGGTGTATTATACC)) was utilized as a negative control.
Results obtained with the empty gRNA vector were arbitrarily set as 100%. The results shown are the average of three independent transfection experiments.
Experiments were also performed with gRNA alone (without Cas9) and the results are shown in (B). (C, D) Effects of gRNA/Cas9 on virus production. Levels
of viruses in the supernatants were determined by ELISA that measures HIV-1 p24 antigen. Results of three independent transfections are shown. (D)
represents the results of experiments performed with gRNA alone (without Cas9). (E, F) Pretreatment with TNF-α does not increase the inhibition of HIV-1 by
gRNA/Cas9. JLat10.6 cells were treated with TNF-α (10 ng/ml) for 16 hours before nucleotransfection with gRNA and hCas9 plasmid DNA. GFP-positive cells
were scored by flow cytometry and the results are shown in (E). Levels of viruses in the supernatants were determined by HIV-1 p24 ELISA and the results
shown in (F). Results are the average of three independent transfections. (G, H) Suppression of HIV-1 by multiple gRNAs that target different HIV-1 DNA sites.
Three different gRNAs were co-transfected with hCas9 plasmid DNA. HIV-1 gene expression (shown in (G)) and virus production (shown in (H)) after TNF-α
treatment were measured as described above. Results shown are the average of three independent transfection experiments. Asterisks indicate P< 0.05
(Mann–Whitney U test, SPSS 16.0).
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the yields of viruses by more than 24-fold (Figure 3G
and H). It is noted that all three combinations contain
gRNAs that target tat/rev, which indicates that tat and rev
sequences may represent vulnerable sites for CRISPR/
Cas9 targeting.
We noted that targeting the pol DNA (T5 to T8) also led
to significant reduction in GFP expression that is driven by
the LTR and viral Tat protein (Figure 3). One possibility is
that Cas9 cleavage of the pol DNA, as guided by T5, T6,
T7 or T8, triggers DNA damage response which causes
histone modification (such as H3K9me3) and consequent
transcription silencing of adjacent genes [17]. To test this,Figure 4 Effect of gRNA/Cas9 treatment on histone modification at H
gene (T5 to T8). Cells were then harvested and subject to ChIP analysis usin
Levels of HIV-1 LTR DNA (shown in (A)) or GFP DNA (shown in (B)) in the i
Results shown are the average of three independent experiments. Asteriskswe treated JLat10.6 cells with control guide RNA or the T5
to T8 HIV-1 guide RNA together with Cas9, followed by
ChIP (chromatin immunoprecipitation) analysis of histone
modification at HIV-1 LTR and GFP regions. Two types of
histone modification were studied, H3K9me3 that marks
transcription suppression and H3K36me3 that marks tran-
scription activation [18]. The results of Figure 4 show that
the LTR DNA or GFP DNA is enriched by more than 2-
fold by the anti-H3K9me3 antibodies in the HIV-1 guide
RNA treated cells as compared to the cells that were
treated with either the empty vector or gRNA targeting lu-
ciferase (T RL). In contrast, neither anti-H3 nor anti-
H3K36me3 antibodies enriched HIV-1 LTR DNA or GFPIV-1 LTR. JLat10.6 cells were treated with gRNAs that target HIV-1 pol
g control IgG, anti-H3, anti-H3K9me3, or anti-H3K36me3 antibodies.
mmunoprecipitated materials were determined by quantitative PCR.
indicate P < 0.05 (Mann–Whitney U test, SPSS 16.0).
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Interestingly, treatment with the GFP gRNA (T GFP) led
to specific enrichment of GFP DNA associated with anti-
H3K9me3 antibody; in contrast, HIV-1 LTR DNA was not
significantly enriched (Figure 4). These data suggest that,
in addition to generate mutations in the target DNA, the
CRISPR/Cas9 machinery also induces H3K9me3 histone
modification at the target site, which contributes to tran-
scription suppression.
In conclusion, results of this study demonstrate the
great potency of the CRISPR/Cas9 system to target and in-
activate HIV-1 proviral DNA in the latent JLat10.6 cell
line. Since JLat10.6 is a clonal cell line in which HIV-1 is
integrated at a specific site in cellular DNA, results in this
study cannot conclude whether the CRISRP/Cas9 system
may target HIV-1 DNA that is integrated at different
cellular DNA loci with different efficiency. Since the
CRISPR/Cas9 complex targets both the transcription inert
and the transcription active HIV-1 DNA with similar effi-
ciency, CRISPR/Cas9 should be effective in eliminating
HIV-1 reservoirs in which HIV-1 exists in a latent state. In
support of our data, recent studies reported suppression
of the HIV-based vectors using the CRISPR/Cas9 system
[19,20]. Both studies tested gRNAs targeting HIV-1 LTR.
We have herein tested 10 target sites across HIV-1 gen-
ome and identified one site in the second exon of Rev
(called T10) that exhibits the highest level of mutation by
Cas9. In a separate study, the CRISPR/Cas9 system was
exploited to successfully generate the CCR5Δ32 deletion
in pluripotent stem cells with 33% efficiency, as compared
to 14% efficiency when the TALENS method was
employed [21]. Together, all these findings support the
utility of the CRISPR/Cas9 system as a new genome edit-
ing approach to eradicate HIV-1. Challenges also exist to
target a highly mutable virus like HIV-1 using the
CRISPR/Cas9 system whose efficacy is largely dependent
on how well the gRNA matches the target viral DNA se-
quence. One solution can be a personalized approach in
which the gRNA is designed to match the HIV-1 se-
quences that are archived in the reservoir of the individual
patient. This effort may especially pay off if such an ap-
proach can be used to cure infected individuals. A second
strategy may involve exploiting multiple gRNAs to target
several relatively conserved sites in the HIV-1 genome in
order to maximize efficacy and minimize virus escape.
With the CRISPR/Cas9 field quickly evolving, new tools
will hopefully emerge to help eradicate HIV in clinical
settings.
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